Interview with Mark Glover , Vice President and Managing Director, Allergan
How have PBS reforms impacted Allergan in Australia? The PBS is a very good system that provides Australians with equity of access and has worked well in the country for…
Address: Level 1, 16 Napier Close DEAKIN ACT 2600,Australia
Tel: (602) 6282 6888
Web: http://www.pharmacouncil.com.au/
The Pharmaceuticals Industry Council is the peak body for Australia’s pharmaceutical and biotechnology industries. It brings together the innovative, generic and biotechnology industries to represent a whole-of-sector approach to addressing opportunities and threats to investment in the sector.
The PIC was established in June 2006, following the three-year implementation of the Government-endorsed Pharmaceuticals Industry Action Agenda. The PIC aims to take forward the work of the PIAA, particularly to double Australia’s share of the global pharmaceuticals industry by 2012.
The biopharmaceuticals sector in Australia employs approximately 34 000 people, exports almost $4 billion worth of medicines annually and invests more than $752 million per year in research and development collaborations with local hospitals, universities and research organisations. The industry is a major innovative contributor to the economy, and one of the most R&D intensive industries in Australia.
Investment, Intellectual Propery Rights, Corporate-Governmental relations
How have PBS reforms impacted Allergan in Australia? The PBS is a very good system that provides Australians with equity of access and has worked well in the country for…
Alphapharm recently celebrated its 25th anniversary. In light of this significant milestone, would you give us a brief introduction to the company? Alphapharm started in 1982 in Brisbane with a…
What impact have the PBS reforms had on sanofi-aventis in Australia? Sanofi-aventis has one of the largest portfolios of medicines in Australia, with over 240 products in the key areas…
Would you please introduce Pretium’s specific service offerings, and the focus within these? Pretium offers a comprehensive range of integrated services across our 4 lines of business – Market Intelligence,…
What are some of the challenges facing pharmaceutical companies in Australia today? There are four major challenges within the Australian pharmaceutical industry at the moment. The increasing complexity of getting…
As ASMI President and Managing Director of Galderma, would you please give us a brief overview of the Australian OTC market and Galderma’s role therein? Galderma is a leading player…
What impact have the PBS reforms had on Amgen in Australia? From a company perspective, biotechnology companies exist in a competitive space. They have predominantly niche medicines with significant competitive…
2006 marked a major milestone, with the Pharmaceutical Industry Action Agenda transformed from a Government-industry initiative into an industry-driven agenda, and the resulting creation of the Pharmaceutical Industry Council (PIC).…
One of the hot topics in the industry is the impact of PBS reforms. Can you speak to recent influence of PBS reforms affecting Novotech’s services in Australia? In our…
To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the association that represents the country’s research-based pharmaceutical industry. With approximately 50 members, the organization…
Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why…
How will the PBS reforms affect Solvay? The easy answer is: heavily. Fortunately, Solvay’s leading product which is still under patent will not be subject to the full August 1…
See our Cookie Privacy Policy Here
